Overview
What is Melanotan 2?
Melanotan 2 is a cyclic lactam analogue of alpha-melanocyte-stimulating hormone (α-MSH) developed at the University of Arizona in the late 1980s. Its cyclized backbone confers markedly greater potency and metabolic stability than the native hormone. Research has examined its non-selective activity across the melanocortin receptor family, with published work spanning melanogenesis, appetite regulation, and central nervous system signaling in cell culture and rodent models.
Melanotan 2 (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂) is supplied strictly as a reference material for in vitro and preclinical investigation. All characterization data described here is drawn from peer-reviewed literature and laboratory analysis; nothing herein constitutes a claim of clinical effect in humans.
Investigational Scope
Documented Research Areas
The following domains summarize directions explored across published studies and laboratory models. Each reflects observations reported in rodent models, in vitro systems, or the peer-reviewed record.
Pigmentation
Melanogenesis & MC1R Signaling
Melanotan 2 is a widely used research tool for MC1R activation. Studies in melanocyte cultures and rodent models have documented increased tyrosinase activity and eumelanin synthesis following exposure, making it a reference agonist in pigmentation biology.
Neuroendocrine
MC4R & Appetite Regulation Models
Research in rodent models has examined Melanotan 2 as an MC4R agonist in studies of food intake and energy balance, with observed reductions in feeding behavior that helped establish the melanocortin system as a regulator of appetite.
CNS
Central Melanocortin Pathways
Published studies have used Melanotan 2 to probe MC3R and MC4R signaling in the central nervous system. This literature contributed directly to the development of the more selective analogue bremelanotide (PT-141).
Photobiology
UV Response & Photoprotection Models
Investigators have examined whether melanocortin-driven eumelanin accumulation alters cellular response to ultraviolet exposure, using Melanotan 2 in cell culture and animal models of UV-induced DNA damage.
Proposed Mechanism
Mechanistic Pathway
Mechanistic steps below are hypothesized from in vitro assays and animal-model data reported in the literature. They describe biochemical interactions observed under controlled experimental conditions.
-
1
Non-Selective Melanocortin Receptor Agonism
Melanotan 2 acts as an agonist at MC1R, MC3R, MC4R, and MC5R with limited discrimination between subtypes. This broad profile makes it a useful comparator against subtype-selective analogues in receptor pharmacology studies.
-
2
Cyclic Lactam Structural Stabilization
A lactam bridge between the Asp and Lys residues constrains the peptide backbone into a conformation that resists enzymatic degradation, producing substantially longer duration of action than linear α-MSH.
-
3
cAMP-Mediated Tyrosinase Upregulation
MC1R binding activates adenylyl cyclase and raises intracellular cAMP, which promotes MITF expression and tyrosinase transcription — the rate-limiting step in melanin biosynthesis documented in melanocyte cultures.
-
4
Hypothalamic MC3R/MC4R Signaling
Central MC3R and MC4R activation in hypothalamic nuclei modulates downstream neural circuits governing energy homeostasis and autonomic output, mechanisms characterized across multiple rodent research models.
Technical Data
Molecular Specifications
| Amino Acid Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ |
| Molecular Weight | 1,024.2 g/mol |
| Molecular Formula | C₅₀H₆₉N₁₅O₉ |
| CAS Number | 121062-08-6 |
| Storage | −20°C long-term, 4°C short-term up to 4 weeks |
References
Selected Literature
The following peer-reviewed references informed the research summaries on this page. Citations are provided for scientific context only.
- Al-Obeidi F, et al. (1989). Potent and prolonged acting cyclic lactam analogues of α-melanotropin: design based on molecular dynamics. Journal of Medicinal Chemistry, 32(12), 2555–2561.
- Dorr RT, et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777–1784.
- Wessells H, et al. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology, 160(2), 389–393.
- Van der Ploeg LH, et al. (2002). A role for the melanocortin 4 receptor in sexual function. Proceedings of the National Academy of Sciences, 99(17), 11381–11386.
- Hadley ME & Dorr RT. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921–930.
Research Disclaimer
This product is intended strictly for laboratory research purposes only. It is not a drug, food, cosmetic, or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or animal consumption. All information presented is derived from published scientific literature and is provided for educational reference only. By purchasing, the buyer affirms they are a qualified researcher or institution and assume full responsibility for the safe and lawful handling of this material.